{"id":"540d4c9f-f745-5827-9bff-e2a935813eb2","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-bioavailability-17-percent","predicate":"limits","statement":"Following intravenous administration of a 1.7 microgram tracer dose of tritiated mebendazole to a man an elimination half-life of 1.16 hours was observed with a volume of distribution of 2.03 litres per kilogram, after oral administration of the same dose the elimination half-life was 0.74 hours, and the bioavailability of mebendazole from the solution was found to be 17%.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"negative","is_public":true,"mechanism_event_id":"4731577f-ae05-5e2f-bb23-ee0b2f2b5bf8","mechanism_event_label":"Swallowed, roughly one sixth of the drug reaches the bloodstream.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"c42f1791-ecdc-584a-b45d-99dc23ededff","slug":"oral-bioavailability","display_name":"Oral bioavailability","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"4731577f-ae05-5e2f-bb23-ee0b2f2b5bf8","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-bioavailability-17-percent-event","event_type":"observed_intervention","label":"Swallowed, roughly one sixth of the drug reaches the bloodstream.","description":"Following intravenous administration of a 1.7 microgram tracer dose of tritiated mebendazole to a man an elimination half-life of 1.16 hours was observed with a volume of distribution of 2.03 litres per kilogram, after oral administration of the same dose the elimination half-life was 0.74 hours, and the bioavailability of mebendazole from the solution was found to be 17%.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"bd95c09d-7613-5fed-b54a-b918e25f6551","slug":"aqueous-solubility","display_name":"Aqueous solubility and dissolution rate of the solid drug","entity_type_key":"cellular_process"},"role":"limiting_property","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"c42f1791-ecdc-584a-b45d-99dc23ededff","slug":"oral-bioavailability","display_name":"Oral bioavailability","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/7126419.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7b69c414a01f82e177ec37b4f362337caf7327e294a13c97d299e9a7ae80a456\", \"start_char\": 0, \"end_char\": 381, \"text_sha256\": \"7b69c414a01f82e177ec37b4f362337caf7327e294a13c97d299e9a7ae80a456\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Tracer study of tritiated mebendazole given intravenously and orally to one man","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"A 1.7 microgram tracer dose by each route","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A single subject and a tracer dose far below any therapeutic amount, so the bioavailability figure is a lower bound on the problem rather than a population value.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Swallowed, roughly one sixth of the drug reaches the bloodstream.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p7126419] The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. (1982). https://pubmed.ncbi.nlm.nih.gov/7126419/ DOI: 10.1111/j.1365-2125.1982.tb02008.x","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole body","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"103c409f-cb4b-5eab-a556-0e69fb3a95f1","evidence_kind":"source_excerpt","locator":"Lines 407-418","start_line":407,"end_line":418,"excerpt":"### mbz-bioavailability-17-percent\nFollowing intravenous administration of a 1.7 microgram tracer dose of tritiated mebendazole to a man an elimination half-life of 1.16 hours was observed with a volume of distribution of 2.03 litres per kilogram, after oral administration of the same dose the elimination half-life was 0.74 hours, and the bioavailability of mebendazole from the solution was found to be 17%.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: Swallowed, roughly one sixth of the drug reaches the bloodstream.\norganism: Human\ntissue_or_cell_type: Whole body\nexperimental_model: Tracer study of tritiated mebendazole given intravenously and orally to one man\nlimitations: A single subject and a tracer dose far below any therapeutic amount, so the bioavailability figure is a lower bound on the problem rather than a population value.\nexposure: A 1.7 microgram tracer dose by each route\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/7126419.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"7b69c414a01f82e177ec37b4f362337caf7327e294a13c97d299e9a7ae80a456\", \"start_char\": 0, \"end_char\": 381, \"text_sha256\": \"7b69c414a01f82e177ec37b4f362337caf7327e294a13c97d299e9a7ae80a456\"}\n[mbz-p7126419] The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. (1982). https://pubmed.ncbi.nlm.nih.gov/7126419/ DOI: 10.1111/j.1365-2125.1982.tb02008.x","model_system":"Tracer study of tritiated mebendazole given intravenously and orally to one man","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p7126419] The pharmacokinetics and bioavailability of mebendazole in man: a pilot study using [3H]-mebendazole. (1982). https://pubmed.ncbi.nlm.nih.gov/7126419/ DOI: 10.1111/j.1365-2125.1982.tb02008.x","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}